Alps Advisors Inc. grew its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 32.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 124,893 shares of the company's stock after purchasing an additional 30,912 shares during the quarter. Alps Advisors Inc. owned approximately 0.13% of Travere Therapeutics worth $7,354,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Jupiter Topco LLC bought a new stake in shares of Travere Therapeutics during the second quarter valued at approximately $643,299,000. Bank of America Corp DE bought a new position in shares of Travere Therapeutics during the 2nd quarter valued at approximately $259,527,000. Assenagon Asset Management S.A. boosted its position in shares of Travere Therapeutics by 168.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,145,414 shares of the company's stock valued at $67,442,000 after acquiring an additional 718,109 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Travere Therapeutics by 50.0% during the 2nd quarter. Wellington Management Group LLP now owns 1,533,080 shares of the company's stock valued at $87,094,000 after acquiring an additional 510,808 shares during the last quarter. Finally, Legal & General Group Plc purchased a new position in shares of Travere Therapeutics in the second quarter valued at $26,723,000.
More Travere Therapeutics News
Here are the key news stories impacting Travere Therapeutics this week:
- Positive Sentiment: Canaccord Genuity raised its price target to $72 from $70 and maintained a Buy rating, signaling continued confidence in the shares. Article: Travere Therapeutics Stock Gets Price Target Increase from Canaccord Genuity Group
- Positive Sentiment: HC Wainwright kept its Buy rating and $67 target while raising its earnings forecasts for 2027–2030, including its 2030 EPS estimate to $6.84 from $5.73. The revisions point to stronger expected longer-term earnings.
- Neutral Sentiment: Analyst actions were mixed: Leerink Partners cut its target to $67 from $78 but retained an Outperform rating, while Guggenheim also lowered its target; the report provided no revised figure. Article: Travere Therapeutics Stock Price Target Cut by Guggenheim
- Negative Sentiment: Travere’s latest quarterly results missed sharply on earnings: EPS was a loss of $0.55 versus the expected loss of $0.06. Revenue beat estimates at $224.56 million and rose 36.2% year over year, but the earnings shortfall contributed to reports of a post-results share-price gap down. Article: Travere Therapeutics Shares Gap Down After Earnings Miss
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on the company. Weiss Ratings restated a "sell (e+)" rating on shares of Travere Therapeutics in a research report on Friday, September 18th. Canaccord Genuity Group lifted their target price on Travere Therapeutics from $70.00 to $72.00 and gave the stock a "buy" rating in a report on Wednesday. HC Wainwright reissued a "buy" rating and set a $67.00 target price on shares of Travere Therapeutics in a research report on Tuesday, September 22nd. Evercore set a $78.00 price target on shares of Travere Therapeutics in a research note on Monday, August 10th. Finally, Citigroup upped their price target on shares of Travere Therapeutics from $70.00 to $85.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Eleven analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $68.45.
Get Our Latest Report on TVTX
Travere Therapeutics Trading Up 1.5%
Shares of NASDAQ:TVTX opened at $49.60 on Friday. Travere Therapeutics, Inc. has a 12-month low of $22.59 and a 12-month high of $68.73. The business's fifty day simple moving average is $57.40 and its 200-day simple moving average is $47.00. The company has a market capitalization of $4.76 billion, a PE ratio of -38.45 and a beta of 1.11. The company has a current ratio of 3.00, a quick ratio of 3.99 and a debt-to-equity ratio of 26.72.
Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.49). The company had revenue of $224.56 million for the quarter, compared to analysts' expectations of $195.29 million. Travere Therapeutics had a negative return on equity of 185.69% and a negative net margin of 18.66%. The company's revenue for the quarter was up 36.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.28 earnings per share. As a group, equities research analysts predict that Travere Therapeutics, Inc. will post -0.90 earnings per share for the current fiscal year.
Insider Activity
In other Travere Therapeutics news, CFO Christopher R. Cline sold 50,508 shares of Travere Therapeutics stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $62.34, for a total value of $3,148,668.72. Following the transaction, the chief financial officer directly owned 87,508 shares of the company's stock, valued at approximately $5,455,248.72. The trade was a 36.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Peter Heerma sold 172,717 shares of the company's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $63.43, for a total value of $10,955,439.31. Following the transaction, the executive vice president directly owned 117,066 shares in the company, valued at approximately $7,425,496.38. The trade was a 59.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,294,029 shares of company stock worth $79,454,261 over the last 90 days. 4.44% of the stock is currently owned by insiders.
Travere Therapeutics Company Profile
(
Free Report)
Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on serious kidney conditions. The company's work centers on addressing diseases with limited treatment options and improving outcomes for patients with progressive renal disorders.
Travere's lead commercial product is FILSPARI (sparsentan), an oral treatment for adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression.
Recommended Stories
Want to see what other hedge funds are holding TVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Travere Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.
While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.